FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Driscoll Martin J 		2. Issuer Name and Ticker or Trading Symbol

JAVELIN PHARMACEUTICALS, INC [ JAV ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

C/O JAVELIN PHARMACEUTICALS, INC, 125 CAMBRIDGEPARK DRIVE 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/2/2010
(Street)

CAMBRIDGE, MA 02140
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   7/2/2010     D    179529   (1) D $2.20   0   D    
Deferred Stock Units   7/2/2010     D    59524   (2) D $2.20   0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $3.45   7/2/2010     D         50000   (3)   6/13/2007   6/13/2016   Common Stock   50000   $0   0   D    
Stock Option (right to buy)   $4.98   7/2/2010     D         41604   (3)     (4) 1/3/2017   Common Stock   41604   $0   0   D    
Stock Option (right to buy)   $3.53   7/2/2010     D         5000   (3)     (5) 1/9/2018   Common Stock   5000   $0   0   D    
Stock Option (right to buy)   $2.86   7/2/2010     D         850000   (3)     (6) 3/3/2018   Common Stock   850000   $0   0   D    
Stock Option (right to buy)   $1.07   7/2/2010     D         255500   (7)     (8) 1/23/2019   Common Stock   255500   $0   0   D    
Stock Option (right to buy)   $1.15   7/2/2010     D         127750   (9)     (10) 3/16/2019   Common Stock   127750   $0   0   D    
Stock Option (right to buy)   $1.26   7/2/2010     D         119885   (11)     (12) 5/1/2019   Common Stock   119885   $0   0   D    

Explanation of Responses:
( 1)  Pursuant to the Agreement and Plan of Merger, dated April 17, 2010, by and among Hospira, Inc., Discus Acquisition Corporation ("Purchaser") and Javelin Pharmaceuticals, Inc. (the "Company"), Purchaser merged with and into the Company on July 2, 2010 (the "Merger"). These shares, which were outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were immediately canceled and converted at the effective time of the Merger into the right to receive cash consideration equal to $2.20 per share.
( 2)  These Deferred Stock Units, which were outstanding and unexercised immediately prior to the Effective Time, accelerated and were immediately canceled, terminated and converted into the right to receive a cash payment equal to $2.20 per share.
( 3)  These options, which were outstanding and unexercised immediately prior to the Effective Time were immediately canceled and terminated.
( 4)  These options vest in 3 equal annual installments beginning after 1/3/2008.
( 5)  These options vest in 3 equal annual installments beginning after 1/9/2009.
( 6)  These options vest in 3 equal annual installments beginning after 3/3/2009.
( 7)  These options, which were outstanding, unexercised and fully vested immediately prior to the Effective Time were immediately canceled, terminated and converted into the right to receive a cash payment of $288,715.00, representing (a) the difference between the exercise price of the option and the merger consideration of $2.20 per share multiplied by (b) the number of shares subject to the option.
( 8)  These options vest in 3 equal annual installments beginning after 1/23/2010.
( 9)  These options, which were outstanding, unexercised and fully vested immediately prior to the Effective Time were immediately canceled, terminated and converted into the right to receive a cash payment of $134,137.50, representing (a) the difference between the exercise price of the option and the merger consideration of $2.20 per share multiplied by (b) the number of shares subject to the option.
( 10)  These options vest in 3 equal annual installments beginning after 3/16/2010.
( 11)  These options, which were outstanding, unexercised and fully vested immediately prior to the Effective Time were immediately canceled, terminated and converted into the right to receive a cash payment of $112,691.90, representing (a) the difference between the exercise price of the option and the merger consideration of $2.20 per share multiplied by (b) the number of shares subject to the option.
( 12)  These options vest in 2 equal installments on the first and second anniversary of the grant date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Driscoll Martin J
C/O JAVELIN PHARMACEUTICALS, INC
125 CAMBRIDGEPARK DRIVE
CAMBRIDGE, MA 02140 		X
Chief Executive Officer

Signatures
/s/ Martin J. Driscoll 7/2/2010
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Javelin Pharmaceuticals (AMEX:JAV)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Javelin Pharmaceuticals Charts.
Javelin Pharmaceuticals (AMEX:JAV)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Javelin Pharmaceuticals Charts.